What is IRLAB Therapeutics AB Book Value per Share?
IRLAB Therapeutics AB's book value per share for the quarter that ended in Mar. 2024 was kr1.48.
During the past 12 months, IRLAB Therapeutics AB's average Book Value Per Share Growth Rate was -66.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -32.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -8.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of IRLAB Therapeutics AB was 28.10% per year. The lowest was -32.20% per year. And the median was 11.00% per year.
During the past 11 years, the highest P/B Ratio of IRLAB Therapeutics AB was 25.39. The lowest was 1.56. And the median was 5.97.
IRLAB Therapeutics AB Book Value per Share Historical Data
The historical data trend for IRLAB Therapeutics AB's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of IRLAB Therapeutics AB's Book Value per Share
For the Biotechnology subindustry, IRLAB Therapeutics AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IRLAB Therapeutics AB's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, IRLAB Therapeutics AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where IRLAB Therapeutics AB's PB Ratio falls into.
IRLAB Therapeutics AB Book Value per Share Calculation
IRLAB Therapeutics AB's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
IRLAB Therapeutics AB (OSTO:IRLAB A) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
IRLAB Therapeutics AB Book Value per Share Related Terms
Thank you for viewing the detailed overview of IRLAB Therapeutics AB's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
IRLAB Therapeutics AB (OSTO:IRLAB A) Business Description
IRLAB Therapeutics AB is a drug discovery and development company providing novel treatments for disorders of the brain. The company focuses on innovative treatments and quality of life for patients with neurological and psychiatric illnesses. It is engaged in programs targeting core dysfunctions in Parkinson's disease and dementias. In addition, it is also involved in the clinical development of novel compounds which aims at offering improved clinical benefit for patients with Parkinson's disease. The company's current clinical candidates, mesdopetam (IRL790) and pirepemat (IRL752), both of which have successfully gone through Phase I safety and Phase IIa efficacy proof-of-concept studies, are now in Phase IIb trials.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OSTO:IRLAB A has been successfully added to your 